Each film coated tablet contains Sorafenib 200mg as Sorafenib Tosylate INN.
Hepatocellular Carcinoma : Sonib is indicated for the treatment of patients with unresectable hepatocellular carcinoma (HCC). Renal Cell Carcinoma : Sonib is indicated for the treatment of patients with advanced renal cell carcinoma (RCC). Use in Special Population : Renal Function Impairment: No dose adjustments are necessary for mild, moderate or severe renal function impairment in patients not undergoing dialysis. Hepatic Function Impairment : Mild (Child-Pugh class A) and moderate (Child-Pugh class B) hepatic function impairment decreased AUC by 23% and 65% respectively. Not studied in severe (Child-Pugh class C) hepatic function impairment.
Each film coated tablet contains Sorafenib 200mg as Sorafenib Tosylate INN.
Hepatocellular Carcinoma : Sonib is indicated for the treatment of patients with unresectable hepatocellular carcinoma (HCC). Renal Cell Carcinoma : Sonib is indicated for the treatment of patients with advanced renal cell carcinoma (RCC). Use in Special Population : Renal Function Impairment: No dose adjustments are necessary for mild, moderate or severe renal function impairment in patients not undergoing dialysis. Hepatic Function Impairment : Mild (Child-Pugh class A) and moderate (Child-Pugh class B) hepatic function impairment decreased AUC by 23% and 65% respectively. Not studied in severe (Child-Pugh class C) hepatic function impairment.
Drug International Limited was incorporated under the Registrar of Joint Stock Companies in 1974 as a Private Limited Company. The company commenced formulation and production in 1983 and emerged as a pioneer in Bangladesh for adding a state of the art oral solid dosage plant. Since inception, Drug International Limited's primary objective has been to meet guidelines provided by major global regulatory bodies such as the World Health Organization Good Manufacturing Practices (WHO cGMP) guidelines.